Literature DB >> 15626832

Myasthenic crisis: a retrospective study.

S Panda1, Vinay Goyal, M Behari, S Singh, T Srivastava.   

Abstract

BACKGROUND AND
OBJECTIVE: Myasthenic crisis (MC) is one of the important and common complications in the natural history of myasthenia gravis (MG). MC can be precipitated by multiple factors including deficiency or excess of the acetylcholinesterase inhibitors (AChEI). Any episode of MC is an emergency requiring aggressive therapy. We studied the demographic, clinical and treatment-related characteristics of patients who developed MC.
MATERIALS AND METHODS: A retrospective study was conducted in patients with MC admitted during a 31-month period from February 1999 to August 2001, at a tertiary care center in India.
RESULTS: Eleven patients (9.69% of the total 114 patients with MG) were admitted with 12 episodes of MC. Mean age at presentation was 39.83 + 13.18 years with male predominance. Seven patients had undergone thymectomy previously; of which 2 had postoperative MC. Six patients had thymoma. Steroid or cholinesterase inhibitor withdrawal and infections were the commonest precipitating factors for MC. Patients required ventilatory support for median 14 days. They responded to low volume of plasma exchange (PE) (mean 854 ml / day with mean 6.5 cycles per patient).
CONCLUSIONS: This report highlights that the subset of Indian patients with MG who are at risk to develop MC belong to the 3rd and 4th decade, have bulbar symptoms at presentation and are associated with thymoma. Patients with MC should have judicious drug adjustments under supervision and should be treated aggressively during impending MC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15626832

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  10 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Long-term outcome of 424 childhood-onset myasthenia gravis patients.

Authors:  Mengcui Gui; Xuan Luo; Jing Lin; Yue Li; Min Zhang; Xiaofan Zhang; Mingshan Yang; Wei Wang; Bitao Bu
Journal:  J Neurol       Date:  2015-01-15       Impact factor: 4.849

3.  Tako-tsubo cardiomyopathy in a patient with myasthenia gravis crisis: a rare clinical association.

Authors:  Sasidharan Bijulal; Sivadasanpillai Harikrishnan; Narayanan Namboodiri; Valaparambil K Ajitkumar; Deepak Gupta; P S Mathuranath
Journal:  BMJ Case Rep       Date:  2009-02-16

4.  Levofloxacin induced myasthenia crisis.

Authors:  A Gunduz; S Turedi; A Kalkan; I Nuhoglu
Journal:  Emerg Med J       Date:  2006-08       Impact factor: 2.740

5.  Predictors of outcome of myasthenic crisis.

Authors:  J Kalita; A K Kohat; U K Misra
Journal:  Neurol Sci       Date:  2014-02-05       Impact factor: 3.307

6.  Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial.

Authors:  Isha Trikha; Sumit Singh; Vinay Goyal; Garima Shukla; Rama Bhasin; Madhuri Behari
Journal:  J Neurol       Date:  2007-08-11       Impact factor: 4.849

7.  Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study.

Authors:  Sudhir Sharma; Vivek Lal; Sudesh Prabhakar; Ritesh Agarwal
Journal:  Ann Indian Acad Neurol       Date:  2013-04       Impact factor: 1.383

8.  The Effect of Immunonutrition on the Postoperative Complications in Thymoma with Myasthenia Gravis.

Authors:  Yanzhong Xin; Hongfei Cai; Lihui Wu; Youbin Cui
Journal:  Mediators Inflamm       Date:  2016-11-10       Impact factor: 4.711

9.  Successfully Treated Hepatitis B Positive Refractory Myasthenic Crisis with Rituximab.

Authors:  R Kumar Singh; Deepika Joshi; Shivani Rath
Journal:  Indian J Crit Care Med       Date:  2020-01

Review 10.  Acetylcholinesterase Inhibitors in Myasthenic Crisis: A Systematic Review of Observational Studies.

Authors:  Mario B Prado; Karen Joy Adiao
Journal:  Neurocrit Care       Date:  2021-07-22       Impact factor: 3.210

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.